<DOC>
	<DOCNO>NCT01460537</DOCNO>
	<brief_summary>This open label Phase I study involves treat subject advanced cancer Copanlisib combination either gemcitabine cisplatin plus gemcitabine . It determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) Copanlisib combination gemcitabine Copanlisib combination cisplatin gemcitabine . The trial involve multiple participate site US . Up maximum 70 subject enrol study .</brief_summary>
	<brief_title>Phase 1 Study PI3 ( Phosphatidylinositol-3 ) -Kinase Inhibitor Copanlisib With Gemcitabine Cisplatin Plus Gemcitabine Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>Subjects , least 18 year age , advance refractory solid tumor gemcitabine ( Treatment A ) cisplatin plus gemcitabine ( Treatment B ) appropriate medical therapy determine treat physician Histological cytological documentation nonhematologic , malignant solid tumor , exclude primary brain spinal tumor , current involvement CNS At least one measurable lesion evaluable disease , per RECIST 1.1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status Assessment 0 1 Life expectancy least 12 week Alanine aminotransferase ( ALT ) ≤ 3.0 x upper limit normal ( ULN ; ≤5 x ULN subject liver involvement cancer ) Aspartate aminotransferase ( AST ) ≤ 3.0 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) Total bilirubin ≤ 2.0 x ULN Serum creatinine ≤ 1.5 x ULN Prothrombin timeinternational normalize ratio/partial thromboplastin time ( PTINR/PTT ) &lt; 1.5 x ULN ( Subjects therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ) . Lowdose aspirin permit ( ≤ 100 mg daily ) . History cardiac disease congestive ; congestive heart failure &gt; New York Heart Association functional classification system ( NYHA ) Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; new onset angina within 3 month prior study entry unstable angina , ventricular cardiac arrhythmia require antiarrhythmic therapy Current diagnosis Type 1 2 diabetes mellitus , hyperglycemia ( define consistent fast blood glucose &gt; 125 mg/dL ) HgBA1c ≥ 7 % Use systemic corticosteroid within 2 week start study treatment ( topical inhale steroid permit ) . Single dose systemic corticosteroid give premedication procedure nonstudy drug may administer 24 hour first dose Copanlisib . Poorly control hypertension , define systolic blood pressure ( BP ) &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Poorly control seizure disorder Subjects undergoing renal dialysis Use strong inhibitor CYP3A4 ( eg , ketoconazole , itraconazole , clarithromycin , ritonavir , indinavir , nelfinavir , nefazodone saquinavir ) strong inducer CYP3A4 ( eg , rifampin ) permit Day 14 Cycle 1 duration study . Anticancer chemotherapy immunotherapy study within 4 week first study treatment Hormonal therapy study within 2 week first study treatment . Bisphosphonate therapy first 2 cycle treatment Biological response modifier , granulocyte colony stimulate factor ( GCSF ) within 4 week first study treatment Radiotherapy target lesion study within 4 week first study treatment Known hypersensitivity study drug active substance excipients preparation Use St John 's Wort prohibit Day 14 duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>phase I</keyword>
	<keyword>phosphatidylinositol-3 kinase inhibitor</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>maximum tolerate dose</keyword>
</DOC>